Vol. 6 No. 11 (2026): November
Reimbursement Recommendations

Ropeginterferon Alfa-2b (Besremi)

decorative image of the issue cover

Published November 17, 2026

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Besremi be reimbursed by public drug plans for the treatment of adult patients with polycythemia vera (PV) requiring cytoreductive therapy if certain conditions are met.
  • The pan-Canadian Oncology Drug Review Expert Review Committee (pERC) determined that it is uncertain whether Besremi demonstrates acceptable clinical value versus hydroxyurea, peginterferon alfa-2a, and ruxolitinib in patients with PV requiring cytoreductive therapy. Given that Besremi is expected to be an alternative treatment to hydroxyurea, acceptable clinical value refers to at least comparable value versus hydroxyurea.
  • Evidence from a clinical trial failed to show that Besremi is noninferior to hydroxyurea at 12 months in patients with PV requiring cytoreductive therapy. However, the evidence from the completed long-term extension study suggested numerical improvements in disease response rates, complete hematological response, molecular response, and change in JAK2 allele burden when Besremi was compared to best available therapy. Evidence from an indirect treatment comparison showed that the complete hematological response was similar between Besremi and peginterferon alfa-2a in patients with PV.
  • pERC has established that there is significant unmet clinical need for additional cytoreductive treatment options for PV. Currently, there are limited treatment options with hydroxyurea used off-label as the main first-line option. There are challenges with hydroxyurea as patients may develop intolerance or resistance; hydroxyurea may be unsuitable for those ofd reproductive age; and there have been recent supply shortages, rendering the need for more treatment options for patients. pERC concluded that Besremi addresses a significant unmet need to a degree that justifies a positive recommendation despite the uncertainty in clinical value.